Abbott Laboratories (ABT) KPIs and segments
Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Abbott Laboratories · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Abbott Laboratories: 64 chỉ số vận hành, trong đó có Continuous Glucose Monitoring (CGM, Diabetes Care Division và Electrophysiology Division, lấy từ 217 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medical Devices($M)2 | 5,853 | 5,539 | 5,675 | 5,448 | 5,369 | 4,895 | 5,052 | 4,747 | 4,734 | 4,453 | 4,443 | ||
International($M) | 3,173 | 3,016 | 3,070 | 2,927 | 2,866 | 2,556 | 2,699 | 2,531 | 2,549 | 2,419 | 2,378 | ||
United States($M) | 2,680 | 2,523 | 2,605 | 2,521 | 2,503 | 2,339 | 2,353 | 2,216 | 2,185 | 2,034 | 2,065 | ||
Diagnostic Products($M)2 | 3,092 | 2,180 | 2,457 | 2,253 | 2,173 | 2,054 | 2,520 | 2,412 | 2,195 | 2,214 | 2,534 | ||
United States($M) | 1,660 | 905 | 967 | 886 | 811 | 871 | 1,055 | 1,032 | 812 | 931 | 1,020 | ||
International($M) | 1,432 | 1,275 | 1,490 | 1,367 | 1,362 | 1,183 | 1,465 | 1,380 | 1,383 | 1,283 | 1,514 | ||
Nutritional Products($M)2 | 2,144 | 2,017 | 1,940 | 2,153 | 2,212 | 2,146 | 2,129 | 2,066 | 2,150 | 2,068 | 2,038 | ||
International($M) | 1,273 | 1,173 | 1,134 | 1,265 | 1,255 | 1,191 | 1,201 | 1,116 | 1,217 | 1,190 | 1,178 | ||
United States($M) | 871 | 844 | 806 | 888 | 957 | 955 | 928 | 950 | 933 | 878 | 860 | ||
Established Pharmaceuticals($M)2 | 1,499 | 1,426 | 1,382 | 1,511 | 1,383 | 1,260 | 1,268 | 1,406 | 1,294 | 1,226 | 1,222 | ||
International($M) | 1,499 | 1,426 | 1,382 | 1,511 | 1,383 | 1,260 | 1,268 | 1,406 | 1,294 | 1,226 | 1,222 | ||
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
International($M) | 7,377 | 6,890 | 7,076 | 7,070 | 6,866 | 6,190 | 6,633 | 6,433 | 6,443 | 6,118 | 6,292 | ||
United States($M) | 5,216 | 4,274 | 4,383 | 4,299 | 4,276 | 4,168 | 4,341 | 4,202 | 3,934 | 3,846 | 3,949 | ||
Medical Devices($M) | 1,969 | 1,893 | 1,978 | 1,829 | 1,796 | 1,609 | 1,773 | 1,513 | 1,507 | 1,360 | 1,501 | ||
Diagnostic Products($M) | 499 | 335 | 609 | 400 | 372 | 359 | 611 | 558 | 430 | 474 | 713 | ||
Established Pharmaceuticals($M) | 382 | 365 | 255 | 391 | 346 | 298 | 271 | 380 | 315 | 267 | 254 | ||
Nutritional Products($M) | 368 | 311 | 386 | 360 | 418 | 394 | 443 | 312 | 373 | 377 | 361 | ||
Medical Devices($M) | 3,928 | 3,725 | 3,681 | 3,611 | 3,297 | 3,142 | 3,107 | 2,906 | |||||
Diagnostic Products($M) | 1,560 | 938 | 963 | 949 | 902 | 1,132 | 992 | 1,026 | |||||
Nutritional Products($M) | 996 | 928 | 930 | 1,057 | 1,022 | 915 | 1,002 | 980 | |||||
Established Pharmaceuticals($M) | 849 | 782 | 797 | 752 | 691 | 762 | 703 | 642 | |||||
Established Pharmaceuticals($M) | -36 | -20 | -59 | -38 | -39 | -33 | -65 | -52 | -37 | -29 | |||
Nutritional Products($M) | -46 | -40 | -71 | -71 | -81 | -79 | -100 | -106 | -103 | -73 | |||
Diagnostic Products($M) | -157 | -128 | -292 | -168 | -166 | -135 | -283 | -183 | -169 | -123 | |||
Medical Devices($M) | -185 | -147 | -217 | -140 | -145 | -156 | -186 | -151 | -158 | -135 | |||
Medical Devices($M) | 11,406 | 10,983 | 10,689 | 10,576 | 10,555 | 10,034 | 9,472 | 9,029 | |||||
Diagnostic Products($M) | 9,709 | 9,631 | 8,273 | 8,201 | 8,177 | 7,840 | 7,678 | 7,767 | |||||
Nutritional Products($M) | 5,278 | 4,903 | 4,791 | 4,891 | 4,910 | 4,635 | 4,404 | 4,270 | |||||
Established Pharmaceuticals($M) | 3,819 | 3,665 | 3,540 | 3,730 | 3,732 | 3,448 | 3,087 | 3,118 | |||||
Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M)($M)2 | 2,100 | 2,000 | 2,000 | 2,000 | 1,900 | 1,700 | 1,800 | 1,700 | 1,600 | 1,500 | 1,400 | ||
CGM (FreeStyle Libre) — Organic / Comparable Sales Growth (%)(%) | 7.7% | 9.5% | 7.6% | 12.2% | 17.2% | 19.6% | 21.6% | 22.8% | 20.7% | 20.4% | 23.3% | ||
CGM (FreeStyle Libre) — Reported Sales Growth (%)(%) | 7.3% | 11.0% | 14.2% | 15.0% | 20.5% | 21.4% | 18.3% | 22.7% | 19.1% | 18.4% | 22.4% | ||
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M)($M)5 | 2,185 | 2,188 | 2,080 | 2,133 | 2,057 | 1,981 | 1,827 | 1,863 | 1,725 | 1,648 | 1,569 | 1,552 | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Organic / Comparable Sales Growth (%)(%) | 6.7% | 9.0% | 7.4% | 11.7% | 16.2% | 18.5% | 19.8% | 20.6% | 19.1% | 18.2% | 20.7% | 20.7% | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Reported Sales Growth (%)(%) | 6.2% | 10.5% | 13.8% | 14.5% | 19.3% | 20.2% | 16.5% | 20.1% | 17.1% | 15.8% | 19.5% | 22.0% | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Foreign Exchange Impact on Sales Growth (%)(%) | 2.8% | 3.1% | 1.7% | -3.3% | -0.5% | -2.0% | -2.4% | -1.2% | 1.3% | ||||
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — U.S. Revenue ($M)($M)2 | 872 | 862 | 822 | 843 | 796 | 794 | 748 | 734 | 673 | 637 | 589 | 601 | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Organic / Comparable Sales Growth (%)(%) | 9.4% | 8.6% | 9.8% | 14.9% | 18.4% | 24.5% | 27.1% | 22.0% | 23.6% | 26.3% | 22.8% | 28.3% | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) U.S. — Reported Sales Growth (%)(%) | 9.4% | 8.6% | 9.8% | 14.9% | 18.4% | 24.5% | 27.1% | 22.0% | 23.6% | 26.3% | 22.8% | 28.3% | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — International Revenue ($M)($M)2 | 1,313 | 1,326 | 1,258 | 1,290 | 1,261 | 1,187 | 1,079 | 1,129 | 1,052 | 1,011 | 980 | 951 | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Organic / Comparable Sales Growth (%)(%) | 4.9% | 9.2% | 5.7% | 9.6% | 14.7% | 14.7% | 15.4% | 19.7% | 16.5% | 13.7% | 19.6% | 16.2% | |
Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) International — Reported Sales Growth (%)(%) | 4.2% | 11.7% | 16.6% | 14.2% | 19.9% | 17.5% | 10.1% | 18.8% | 13.3% | 10.0% | 17.6% | 18.4% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M)($M)5 | 873 | 861 | 788 | 730 | 705 | 700 | 629 | 643 | 610 | 627 | 587 | 593 | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%)(%) | 15.5% | 13.4% | 12.5% | 12.5% | 13.7% | 10.3% | 9.9% | 8.8% | 14.3% | 16.7% | 18.4% | 21.2% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Reported Sales Growth (%)(%) | 15.0% | 14.0% | 16.7% | 13.5% | 15.6% | 11.5% | 7.3% | 8.3% | 12.2% | 13.3% | 16.2% | 21.5% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.0% | 1.9% | 1.2% | -2.6% | -0.5% | -2.1% | -3.4% | -2.2% | 0.3% | ||||
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — U.S. Revenue ($M)($M)2 | 429 | 420 | 378 | 340 | 322 | 322 | 299 | 300 | 285 | 287 | 269 | 279 | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Organic / Comparable Sales Growth (%)(%) | 18.1% | 15.9% | 13.7% | 13.1% | 13.2% | 12.2% | 11.1% | 7.7% | 15.8% | 16.8% | 13.1% | 15.0% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) U.S. — Reported Sales Growth (%)(%) | 18.1% | 15.9% | 13.7% | 13.1% | 13.2% | 12.2% | 11.1% | 7.7% | 15.8% | 16.8% | 13.1% | 15.0% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — International Revenue ($M)($M)2 | 444 | 441 | 410 | 390 | 383 | 378 | 330 | 343 | 325 | 340 | 318 | 314 | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Organic / Comparable Sales Growth (%)(%) | 13.1% | 11.1% | 11.2% | 11.9% | 14.1% | 8.8% | 8.8% | 9.8% | 13.0% | 16.7% | 23.0% | 27.3% | |
Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) International — Reported Sales Growth (%)(%) | 12.2% | 12.3% | 19.6% | 13.9% | 17.6% | 10.9% | 4.0% | 8.8% | 9.2% | 10.5% | 18.9% | 28.0% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Worldwide Revenue ($M)($M)5 | 592 | 597 | 578 | 675 | 635 | 636 | 577 | 609 | 558 | 564 | 515 | 498 | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Organic / Comparable Sales Growth (%)(%) | 6.9% | 5.7% | 6.8% | 8.7% | 11.3% | 11.7% | 14.7% | 22.6% | 16.5% | 15.6% | 13.0% | 11.4% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Reported Sales Growth (%)(%) | 1.9% | 2.7% | 9.0% | 10.8% | 13.6% | 13.0% | 11.9% | 22.4% | 14.6% | 13.2% | 11.7% | 12.9% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Foreign Exchange Impact on Sales Growth (%)(%) | 2.1% | 2.3% | 1.3% | -2.8% | -0.2% | -1.9% | -2.4% | -1.3% | 1.5% | ||||
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — U.S. Revenue ($M)($M)2 | 228 | 225 | 224 | 304 | 297 | 289 | 282 | 290 | 270 | 258 | 233 | 231 | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Organic / Comparable Sales Growth (%)(%) | -2.3% | -0.9% | -3.6% | 4.8% | 10.1% | 12.2% | 20.9% | 25.7% | 21.1% | 17.9% | 10.8% | 7.9% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) U.S. — Reported Sales Growth (%)(%) | -11.1% | -9.8% | -9.5% | 4.8% | 10.1% | 12.2% | 20.9% | 25.7% | 21.1% | 17.9% | 10.8% | 7.9% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — International Revenue ($M)($M)2 | 364 | 372 | 354 | 371 | 338 | 347 | 295 | 319 | 288 | 306 | 282 | 267 | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Organic / Comparable Sales Growth (%)(%) | 13.5% | 10.2% | 15.0% | 12.3% | 12.4% | 11.4% | 9.6% | 20.0% | 12.6% | 13.8% | 14.8% | 14.7% | |
Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) International — Reported Sales Growth (%)(%) | 12.2% | 12.1% | 25.2% | 16.3% | 16.9% | 13.7% | 4.6% | 19.5% | 9.2% | 9.4% | 12.5% | 17.6% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Worldwide Revenue ($M)($M)5 | 752 | 743 | 684 | 705 | 686 | 673 | 585 | 624 | 597 | 607 | 562 | 582 | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Organic / Comparable Sales Growth (%)(%) | 10.0% | 9.5% | 12.5% | 11.5% | 13.0% | 9.8% | 6.1% | 7.2% | 7.0% | 5.9% | 7.5% | 12.1% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Reported Sales Growth (%)(%) | 9.7% | 10.4% | 17.0% | 13.1% | 15.0% | 10.9% | 4.0% | 7.1% | 5.9% | 4.2% | 6.8% | 13.3% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.6% | 2.0% | 1.1% | -2.1% | -0.1% | -1.1% | -1.7% | -0.7% | 1.2% | ||||
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — U.S. Revenue ($M)($M)2 | 380 | 377 | 339 | 340 | 350 | 340 | 304 | 303 | 288 | 292 | 271 | 285 | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%)(%) | 9.0% | 10.7% | 11.5% | 12.8% | 21.1% | 16.5% | 12.3% | 6.0% | 6.0% | 8.5% | 4.5% | 12.0% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Reported Sales Growth (%)(%) | 9.0% | 10.7% | 11.5% | 12.8% | 21.1% | 16.5% | 12.3% | 6.0% | 6.0% | 8.5% | 4.5% | 12.0% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — International Revenue ($M)($M)2 | 372 | 366 | 345 | 365 | 336 | 333 | 281 | 321 | 309 | 315 | 291 | 297 | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Organic / Comparable Sales Growth (%)(%) | 11.0% | 8.3% | 13.5% | 10.2% | 5.5% | 3.6% | 0.3% | 8.4% | 7.9% | 3.7% | 10.3% | 12.1% | |
Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%)(%) | 10.4% | 10.0% | 22.9% | 13.4% | 9.3% | 5.7% | -3.7% | 8.2% | 5.7% | 0.4% | 9.0% | 14.5% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Worldwide Revenue ($M)($M)5 | 387 | 401 | 389 | 375 | 366 | 368 | 339 | 331 | 322 | 321 | 305 | 301 | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Organic / Comparable Sales Growth (%)(%) | 6.0% | 8.7% | 12.2% | 12.1% | 12.1% | 14.0% | 12.4% | 9.6% | 14.4% | 8.9% | 8.4% | 15.4% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Reported Sales Growth (%)(%) | 5.8% | 9.0% | 14.6% | 13.2% | 13.3% | 14.7% | 11.4% | 9.9% | 14.0% | 8.6% | 8.5% | 16.6% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.1% | 1.2% | 0.7% | -1.0% | 0.3% | -0.4% | -0.3% | 0.1% | 1.2% | ||||
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — U.S. Revenue ($M)($M)2 | 303 | 313 | 292 | 283 | 280 | 282 | 262 | 253 | 252 | 244 | 237 | 227 | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Organic / Comparable Sales Growth (%)(%) | 8.4% | 10.9% | 11.4% | 11.7% | 10.7% | 15.8% | 10.6% | 11.5% | 16.7% | 7.7% | 8.7% | 13.6% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) U.S. — Reported Sales Growth (%)(%) | 8.4% | 10.9% | 11.4% | 11.7% | 10.7% | 15.8% | 10.6% | 11.5% | 16.7% | 7.7% | 8.7% | 13.6% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — International Revenue ($M)($M)2 | 84 | 88 | 97 | 92 | 86 | 86 | 77 | 78 | 70 | 77 | 68 | 74 | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Organic / Comparable Sales Growth (%)(%) | -1.6% | 1.3% | 14.9% | 13.4% | 17.2% | 8.4% | 19.1% | 4.1% | 6.6% | 12.8% | 7.1% | 21.4% | |
Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) International — Reported Sales Growth (%)(%) | -2.7% | 3.0% | 25.2% | 17.9% | 22.6% | 11.2% | 14.3% | 5.0% | 5.2% | 11.4% | 7.7% | 26.6% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M)($M)5 | 786 | 803 | 777 | 783 | 745 | 757 | 710 | 725 | 699 | 724 | 689 | 677 | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Organic / Comparable Sales Growth (%)(%) | 5.7% | 5.1% | 4.9% | 6.5% | 4.7% | 3.5% | 5.7% | 6.8% | 4.9% | 1.2% | 5.8% | 4.5% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Reported Sales Growth (%)(%) | 5.4% | 6.1% | 9.5% | 8.0% | 6.6% | 4.5% | 3.0% | 7.1% | 3.9% | 1.3% | 11.7% | 12.0% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.5% | 1.9% | 1.0% | -2.7% | 0.3% | -1.0% | -2.0% | -1.0% | 1.1% | ||||
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — U.S. Revenue ($M)($M)2 | 290 | 294 | 291 | 287 | 280 | 283 | 268 | 269 | 258 | 275 | 254 | 245 | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Organic / Comparable Sales Growth (%)(%) | 3.4% | 3.9% | 8.6% | 6.5% | 8.5% | 3.0% | 5.5% | 9.7% | 2.8% | -0.8% | -1.8% | -2.5% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) U.S. — Reported Sales Growth (%)(%) | 3.4% | 3.9% | 8.6% | 6.5% | 8.5% | 3.0% | 5.5% | 9.7% | 2.8% | 4.3% | 16.4% | 14.8% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M)($M)2 | 496 | 509 | 486 | 496 | 465 | 474 | 442 | 456 | 441 | 449 | 435 | 432 | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Organic / Comparable Sales Growth (%)(%) | 7.1% | 5.8% | 2.7% | 6.6% | 2.5% | 3.8% | 5.8% | 5.2% | 6.2% | 2.5% | 9.9% | 8.3% | |
Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) International — Reported Sales Growth (%)(%) | 6.7% | 7.5% | 10.0% | 8.9% | 5.5% | 5.4% | 1.6% | 5.7% | 4.5% | -0.4% | 9.1% | 10.4% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M)($M)5 | 251 | 260 | 243 | 274 | 254 | 254 | 228 | 257 | 236 | 243 | 226 | 240 | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Organic / Comparable Sales Growth (%)(%) | -1.1% | 1.2% | 4.1% | 5.6% | 6.8% | 4.3% | 2.2% | 8.4% | 5.2% | 8.2% | 17.4% | 18.8% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Reported Sales Growth (%)(%) | -1.2% | 2.0% | 6.8% | 6.5% | 7.6% | 4.6% | 1.0% | 7.7% | 3.8% | 7.0% | 15.3% | 18.8% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Foreign Exchange Impact on Sales Growth (%)(%) | 0.9% | 0.8% | 0.3% | -1.2% | -0.7% | -1.4% | -1.2% | -2.1% | |||||
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — U.S. Revenue ($M)($M)2 | 185 | 189 | 177 | 208 | 196 | 193 | 176 | 204 | 190 | 192 | 181 | 197 | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Organic / Comparable Sales Growth (%)(%) | -5.6% | -2.1% | 0.7% | 1.9% | 3.3% | 0.4% | -2.8% | 4.2% | 0.8% | 3.7% | 16.8% | 20.8% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) U.S. — Reported Sales Growth (%)(%) | -5.6% | -2.1% | 0.7% | 1.9% | 3.3% | 0.4% | -2.8% | 4.2% | 0.8% | 3.7% | 16.8% | 20.8% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — International Revenue ($M)($M)2 | 66 | 71 | 66 | 66 | 58 | 61 | 52 | 53 | 46 | 51 | 45 | 43 | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Organic / Comparable Sales Growth (%)(%) | 13.9% | 11.3% | 15.5% | 19.6% | 21.2% | 18.7% | 22.7% | 27.8% | 25.7% | 28.4% | 19.6% | 10.2% | |
Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%)(%) | 13.6% | 14.7% | 27.2% | 23.8% | 24.9% | 20.4% | 16.3% | 23.9% | 17.8% | 21.7% | 9.8% | 10.2% | |
Medical Devices Segment Total — Worldwide Revenue ($M)($M)8 | 5,826 | 5,853 | 5,539 | 5,675 | 5,448 | 5,369 | 4,895 | 5,052 | 4,747 | 4,734 | 4,453 | 4,443 | |
Medical Devices Segment Total — Organic / Comparable Sales Growth (%)(%) | 7.8% | 8.4% | 8.5% | 10.4% | 12.5% | 12.2% | 12.6% | 14.0% | 13.3% | 12.1% | 14.3% | 15.4% | |
Medical Devices Segment Total — Reported Sales Growth (%)(%) | 6.9% | 9.0% | 13.2% | 12.3% | 14.8% | 13.4% | 9.9% | 13.7% | 11.7% | 10.2% | 14.2% | 17.5% | |
Medical Devices Segment Total — Foreign Exchange Impact on Sales Growth (%)(%) | 1.9% | 2.3% | 1.2% | -2.7% | -0.3% | -1.6% | -2.2% | -1.2% | 1.0% | ||||
Medical Devices Segment Total — U.S. Revenue ($M)($M)2 | 2,687 | 2,680 | 2,523 | 2,605 | 2,521 | 2,503 | 2,339 | 2,353 | 2,216 | 2,185 | 2,034 | 2,065 | |
Medical Devices Segment Total U.S. — Organic / Comparable Sales Growth (%)(%) | 7.6% | 8.0% | 8.7% | 10.7% | 13.8% | 14.6% | 15.0% | 14.0% | 14.2% | 13.5% | 12.1% | 15.5% | |
Medical Devices Segment Total U.S. — Reported Sales Growth (%)(%) | 6.6% | 7.0% | 7.9% | 10.7% | 13.8% | 14.6% | 15.0% | 14.0% | 14.2% | 14.2% | 14.4% | 17.6% | |
Medical Devices Segment Total — International Revenue ($M)($M)2 | 3,139 | 3,173 | 3,016 | 3,070 | 2,927 | 2,866 | 2,556 | 2,699 | 2,531 | 2,549 | 2,419 | 2,378 | |
Medical Devices Segment Total International — Organic / Comparable Sales Growth (%)(%) | 8.0% | 8.7% | 8.3% | 10.1% | 11.3% | 10.1% | 10.5% | 14.0% | 12.5% | 10.9% | 16.1% | 15.4% | |
Medical Devices Segment Total International — Reported Sales Growth (%)(%) | 7.2% | 10.7% | 18.0% | 13.7% | 15.6% | 12.4% | 5.7% | 13.5% | 9.6% | 7.0% | 14.0% | 17.5% | |
Medical Devices — Remaining Performance Obligations / Contract Backlog ($M)($M) | 455 | 429 | 444 | 436 | 427 | 423 | 440 | 466 | 493 | 495 | 478 | ||
Medical Devices — Segment Research & Development Expense ($M)($M) | 470 | 444 | 460 | 462 | 430 | 401 | 391 | 408 | 379 | 368 | |||
Medical Devices — Segment Property & Equipment Additions ($M)($M) | 185 | 147 | 217 | 140 | 145 | 156 | 186 | 151 | 158 | 135 | |||
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M)($M)7 | 1,438 | 1,418 | 1,272 | 1,461 | 1,364 | 1,358 | 1,177 | 1,387 | 1,314 | 1,329 | 1,205 | 1,370 | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Organic / Comparable Sales Growth (%)(%) | 5.4% | 3.2% | 3.3% | 3.6% | 2.2% | 1.6% | 0.9% | 3.8% | 4.3% | 8.6% | 5.9% | 9.1% | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Reported Sales Growth (%)(%) | 5.4% | 4.4% | 8.1% | 5.3% | 3.8% | 2.2% | -2.3% | 1.3% | 2.8% | 2.0% | 8.4% | ||
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.7% | 1.6% | 0.6% | -3.2% | -2.5% | -4.3% | -5.8% | -3.9% | -0.7% | ||||
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — U.S. Revenue ($M)($M)2 | 389 | 377 | 347 | 376 | 366 | 351 | 332 | 363 | 332 | 327 | 310 | 326 | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Organic / Comparable Sales Growth (%)(%) | 6.3% | 7.5% | 4.5% | 3.6% | 10.4% | 7.3% | 7.1% | 11.9% | 4.8% | 5.3% | 7.7% | 8.8% | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) U.S. — Reported Sales Growth (%)(%) | 6.3% | 7.5% | 4.5% | 3.6% | 10.4% | 7.3% | 7.1% | 11.6% | 4.5% | 5.1% | 7.3% | 8.3% | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — International Revenue ($M)($M)2 | 1,049 | 1,041 | 925 | 1,085 | 998 | 1,007 | 845 | 1,024 | 982 | 1,002 | 895 | 1,044 | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Organic / Comparable Sales Growth (%)(%) | 5.1% | 1.7% | 2.8% | 3.6% | -0.6% | -0.3% | -1.3% | 1.5% | 4.4% | 9.9% | 5.7% | 10.0% | |
Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) International — Reported Sales Growth (%)(%) | 5.1% | 3.4% | 9.5% | 5.9% | 1.6% | 0.5% | -5.6% | -1.9% | -1.5% | 2.1% | 0.2% | 8.4% | |
Core Laboratory — Organic Sales Growth Excl. COVID-19 Testing (%)(%) | 4.0% | 4.5% | 8.8% | 6.2% | 9.7% | ||||||||
Core Laboratory — COVID-19 Testing Sales ($M)($M)2 | 2 | 3 | 2 | 3 | 4 | ||||||||
Core Laboratory — U.S. COVID-19 Testing Sales ($M)($M) | 1 | 1 | 1 | 1 | 1 | ||||||||
Core Laboratory — International COVID-19 Testing Sales ($M)($M) | 1 | 2 | 1 | 2 | 3 | ||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M)($M)3 | 968 | 919 | 96 | 0 | 0 | ||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Organic / Comparable Sales Growth (%)(%) | 13.8% | 13.3% | 13.4% | ||||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — U.S. Revenue ($M)($M)1 | 938 | 890 | 93 | ||||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) U.S. — Organic / Comparable Sales Growth (%)(%) | 13.9% | 13.3% | 13.2% | ||||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — International Revenue ($M)($M)1 | 30 | 29 | 3 | ||||||||||
Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) International — Organic / Comparable Sales Growth (%)(%) | 12.1% | 13.8% | 19.2% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M)($M)4 | 899 | 755 | 812 | 815 | 877 | ||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Organic / Comparable Sales Growth (%)(%) | 0.9% | -8.0% | -9.6% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Reported Sales Growth (%)(%) | 1.1% | -7.3% | -7.4% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — U.S. Revenue ($M)($M)2 | 526 | 393 | 465 | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Organic / Comparable Sales Growth (%)(%) | 1.1% | -14.5% | -13.8% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) U.S. — Reported Sales Growth (%)(%) | 1.1% | -14.5% | -13.8% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — International Revenue ($M)($M)2 | 373 | 362 | 347 | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Organic / Comparable Sales Growth (%)(%) | 0.7% | 0.5% | -2.7% | ||||||||||
Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) International — Reported Sales Growth (%)(%) | 1.0% | 2.0% | 2.8% | ||||||||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M)($M)7 | 697 | 600 | 544 | 613 | 849 | 824 | 583 | 741 | 862 | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%)(%) | -18.1% | -27.7% | -6.8% | -16.1% | -1.0% | -3.0% | -19.8% | -38.7% | -49.2% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%)(%) | -17.8% | -27.3% | -6.7% | -17.3% | -1.6% | -4.4% | -21.3% | -39.5% | -49.3% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%)(%) | 0.3% | 0.4% | 0.1% | -1.2% | -0.6% | -1.4% | -1.5% | -0.8% | -0.1% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M)($M)2 | 445 | 373 | 321 | 399 | 554 | 560 | 345 | 481 | 543 | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Organic / Comparable Sales Growth (%)(%) | -19.7% | -33.5% | -7.1% | -16.9% | 30.0% | -1.0% | -6.6% | 6.9% | -29.2% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) U.S. — Reported Sales Growth (%)(%) | -19.7% | -33.5% | -7.1% | -16.9% | 2.1% | -0.2% | -32.1% | -46.9% | -55.3% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — International Revenue ($M)($M)2 | 252 | 227 | 223 | 214 | 295 | 264 | 238 | 260 | 319 | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Organic / Comparable Sales Growth (%)(%) | -14.9% | -15.6% | -6.3% | -14.6% | -0.6% | 2.8% | 11.0% | 3.5% | 18.6% | ||||
Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) International — Reported Sales Growth (%)(%) | -14.1% | -14.2% | -6.1% | -17.9% | -7.9% | -12.2% | 2.1% | -18.3% | -34.4% | ||||
Rapid Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%) | 16.4% | 0.4% | 0.4% | 5.6% | -13.7% | ||||||||
Rapid Diagnostics — COVID-19 Testing Sales ($M)($M)2 | 172 | 259 | 97 | 197 | 277 | ||||||||
Rapid Diagnostics — U.S. COVID-19 Testing Sales ($M)($M) | 132 | 203 | 66 | 149 | 218 | ||||||||
Rapid Diagnostics — International COVID-19 Testing Sales ($M)($M) | 40 | 56 | 31 | 48 | 59 | ||||||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M)($M)7 | 141 | 131 | 123 | 122 | 137 | 128 | 127 | 129 | 153 | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%)(%) | 1.1% | 0.8% | -3.4% | -3.5% | -10.2% | -2.1% | -9.4% | -11.7% | -14.9% | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Reported Sales Growth (%)(%) | 3.2% | 2.6% | -2.7% | -5.9% | -10.5% | -3.6% | -10.3% | -11.9% | -14.6% | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Foreign Exchange Impact on Sales Growth (%)(%) | 2.1% | 1.8% | 0.7% | -2.4% | -0.3% | -1.5% | -0.9% | -0.2% | 0.3% | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — U.S. Revenue ($M)($M)2 | 39 | 36 | 35 | 40 | 38 | 37 | 33 | 42 | 44 | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%)(%) | 2.9% | -1.5% | 5.5% | -4.4% | -7.2% | 4.5% | -19.0% | 6.2% | -12.6% | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Reported Sales Growth (%)(%) | 2.9% | -1.5% | 5.5% | -4.4% | -13.9% | -2.8% | -22.5% | -10.6% | -27.7% | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M)($M)2 | 102 | 95 | 88 | 82 | 99 | 91 | 94 | 87 | 109 | ||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Organic / Comparable Sales Growth (%)(%) | 0.4% | 1.7% | -6.5% | -3.1% | -7.5% | 0.8% | -3.6% | 8.2% | |||||
Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%)(%) | 3.3% | 4.3% | -5.6% | -6.7% | -9.1% | -3.9% | -4.9% | -12.5% | -7.8% | ||||
Molecular Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)(%) | -7.4% | 1.8% | -5.6% | -0.8% | 1.7% | ||||||||
Molecular Diagnostics — COVID-19 Testing Sales ($M)($M)2 | 2 | 3 | 3 | 4 | 7 | ||||||||
Molecular Diagnostics — U.S. COVID-19 Testing Sales ($M)($M) | 1 | 2 | 2 | 3 | 5 | ||||||||
Molecular Diagnostics — International COVID-19 Testing Sales ($M)($M) | 1 | 1 | 1 | 1 | 2 | ||||||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M)($M)5 | 158 | 158 | 148 | 142 | 147 | 146 | 156 | 139 | 149 | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Organic / Comparable Sales Growth (%)(%) | 7.1% | 7.8% | -5.2% | 3.2% | -1.4% | 4.6% | 10.0% | 3.6% | 13.0% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Reported Sales Growth (%)(%) | 7.5% | 8.2% | -5.1% | 2.4% | -1.3% | 4.4% | 9.9% | 3.7% | 13.6% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Foreign Exchange Impact on Sales Growth (%)(%) | 0.4% | 0.4% | 0.1% | -0.8% | 0.1% | -0.2% | -0.1% | 0.1% | 0.6% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — U.S. Revenue ($M)($M)2 | 107 | 111 | 104 | 100 | 100 | 103 | 107 | 98 | 107 | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Organic / Comparable Sales Growth (%)(%) | 6.5% | 7.9% | -2.0% | 1.5% | -6.1% | 6.0% | 8.1% | 5.6% | 20.7% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) U.S. — Reported Sales Growth (%)(%) | 6.5% | 7.9% | -2.0% | 1.5% | -6.1% | 6.0% | 8.1% | 5.6% | 20.7% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — International Revenue ($M)($M)2 | 51 | 47 | 44 | 42 | 47 | 43 | 49 | 41 | 42 | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Organic / Comparable Sales Growth (%)(%) | 8.3% | 7.7% | -12.1% | 7.3% | 10.7% | 1.3% | 14.5% | -0.8% | -2.9% | ||||
Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) International — Reported Sales Growth (%)(%) | 9.8% | 8.9% | -11.9% | 4.4% | 11.0% | 0.7% | 14.1% | -0.6% | -1.0% | ||||
Global COVID-19 Testing-Related Sales ($M)($M)2 | 89 | 69 | 55 | 84 | 176 | 265 | 102 | 204 | 288 | ||||
Diagnostics Segment — Organic Sales Growth Excl. COVID-19 Testing (%)(%) | -0.2% | 0.4% | 0.8% | 6.1% | 3.3% | 5.9% | 5.4% | 2.2% | |||||
Diagnostics Segment — COVID-19 Testing YoY Impact on Sales Growth (%)(%) | -3.4% | -8.2% | -2.2% | -5.1% | -1.9% | -7.4% | -20.9% | -24.5% | |||||
Diagnostics Segment Total — Worldwide Revenue ($M)($M)8 | 3,305 | 3,092 | 2,180 | 2,457 | 2,253 | 2,173 | 2,054 | 2,520 | 2,412 | 2,195 | 2,214 | 2,534 | |
Diagnostics Segment Total — Organic / Comparable Sales Growth (%)(%) | 6.4% | 2.9% | 1.8% | -3.6% | -7.8% | -1.4% | -4.9% | 1.0% | 1.4% | -1.5% | -15.5% | -22.3% | |
Diagnostics Segment Total — Reported Sales Growth (%)(%) | 46.7% | 42.3% | 6.1% | -2.5% | -6.6% | -1.0% | -7.2% | -0.6% | -1.5% | -5.3% | -17.6% | -22.7% | |
Diagnostics Segment Total — Foreign Exchange Impact on Sales Growth (%)(%) | 1.1% | 1.2% | 0.4% | -2.3% | -1.6% | -2.9% | -3.8% | -2.1% | -0.4% | ||||
Diagnostics Segment Total — U.S. Revenue ($M)($M)2 | 1,853 | 1,660 | 905 | 967 | 886 | 811 | 871 | 1,055 | 1,032 | 812 | 931 | 1,020 | |
Diagnostics Segment Total U.S. — Organic / Comparable Sales Growth (%)(%) | 8.4% | 4.0% | 2.0% | -8.4% | -14.1% | -0.1% | -6.4% | 15.9% | 2.4% | -0.3% | 7.0% | -10.7% | |
Diagnostics Segment Total U.S. — Reported Sales Growth (%)(%) | 109.2% | 104.8% | 3.8% | -8.4% | -14.1% | -0.1% | -6.4% | 3.5% | 1.8% | -15.5% | -30.3% | -38.8% | |
Diagnostics Segment Total — International Revenue ($M)($M)2 | 1,452 | 1,432 | 1,275 | 1,490 | 1,367 | 1,362 | 1,183 | 1,465 | 1,380 | 1,383 | 1,283 | 1,514 | |
Diagnostics Segment Total International — Organic / Comparable Sales Growth (%)(%) | 4.0% | 1.6% | 1.6% | -0.2% | -3.1% | -2.2% | -3.8% | 0.8% | 3.8% | 9.5% | 4.4% | 10.9% | |
Diagnostics Segment Total International — Reported Sales Growth (%)(%) | 6.2% | 5.1% | 7.8% | 1.8% | -1.0% | -1.5% | -7.8% | -3.4% | -3.8% | 1.9% | -5.1% | -6.0% | |
Diagnostics — Remaining Performance Obligations / Long-Term Reagent & Instrument Backlog ($M)($M) | 6,200 | 6,200 | 6,100 | 6,000 | 5,900 | 5,700 | 5,500 | 5,300 | 4,800 | 4,500 | 4,400 | ||
Diagnostics — Segment Research & Development Expense ($M)($M) | 268 | 155 | 147 | 150 | 154 | 151 | 174 | 165 | 162 | 155 | |||
Diagnostics — Segment Property & Equipment Additions ($M)($M) | 157 | 128 | 292 | 168 | 166 | 135 | 283 | 183 | 169 | 123 | |||
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M)($M)5 | 1,063 | 1,025 | 953 | 902 | 977 | 1,054 | 1,041 | 1,000 | 955 | 1,059 | 1,009 | 985 | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Organic / Comparable Sales Growth (%)(%) | 8.7% | -3.1% | -9.7% | -10.1% | 2.4% | 0.2% | 4.9% | 2.5% | -2.7% | 5.0% | 10.5% | 14.5% | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Reported Sales Growth (%)(%) | 8.8% | -2.7% | -8.5% | -9.8% | 2.3% | -0.4% | 3.2% | 1.5% | -4.5% | 3.4% | 9.2% | 11.8% | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Foreign Exchange Impact on Sales Growth (%)(%) | 0.3% | -0.1% | -0.6% | -1.7% | -1.0% | -1.8% | -1.6% | -1.3% | -0.5% | ||||
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — U.S. Revenue ($M)($M)2 | 577 | 525 | 511 | 463 | 520 | 587 | 588 | 562 | 568 | 564 | 514 | 505 | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Organic / Comparable Sales Growth (%)(%) | 11.0% | -10.7% | -13.0% | -17.7% | -8.4% | 4.2% | 14.2% | 11.3% | 12.2% | 11.3% | 12.0% | 11.4% | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) U.S. — Reported Sales Growth (%)(%) | 11.0% | -10.7% | -13.0% | -17.7% | -8.4% | 4.2% | 14.2% | 11.3% | 12.2% | 11.3% | 12.0% | 11.4% | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — International Revenue ($M)($M)2 | 486 | 500 | 442 | 439 | 457 | 467 | 453 | 438 | 387 | 495 | 495 | 480 | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Organic / Comparable Sales Growth (%)(%) | 6.0% | 6.4% | -5.3% | -0.3% | 18.2% | -4.5% | -4.8% | -6.7% | -18.0% | -1.0% | 8.9% | 17.9% | |
Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) International — Reported Sales Growth (%)(%) | 6.4% | 7.3% | -2.6% | 0.3% | 17.9% | -5.7% | -8.4% | -8.9% | -21.6% | -4.4% | 6.4% | 12.3% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Worldwide Revenue ($M)($M)5 | 1,199 | 1,119 | 1,064 | 1,038 | 1,176 | 1,158 | 1,105 | 1,129 | 1,111 | 1,091 | 1,059 | 1,053 | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Organic / Comparable Sales Growth (%)(%) | 1.8% | -4.0% | -5.9% | -8.2% | 5.4% | 6.6% | 8.7% | 11.4% | 9.1% | 9.9% | 5.3% | 13.4% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Reported Sales Growth (%)(%) | 2.0% | -3.4% | -3.6% | -8.1% | 5.8% | 6.1% | 4.4% | 7.4% | 3.6% | 3.7% | 1.5% | 12.5% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — Foreign Exchange Impact on Sales Growth (%)(%) | 0.1% | 0.4% | -0.5% | -2.9% | -2.3% | -4.4% | -5.4% | -3.8% | -0.9% | ||||
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — U.S. Revenue ($M)($M)2 | 381 | 346 | 333 | 343 | 368 | 370 | 367 | 366 | 382 | 369 | 364 | 355 | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Organic / Comparable Sales Growth (%)(%) | 3.5% | -6.4% | -9.2% | -6.3% | -3.8% | 0.2% | 4.8% | 8.1% | 11.5% | 0.8% | 3.0% | 4.0% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) U.S. — Reported Sales Growth (%)(%) | 3.5% | -6.4% | -9.2% | -6.3% | -3.8% | 0.2% | 1.1% | 3.2% | 7.9% | -1.2% | 3.0% | 4.0% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) — International Revenue ($M)($M)2 | 818 | 773 | 731 | 695 | 808 | 788 | 738 | 763 | 729 | 722 | 695 | 698 | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Organic / Comparable Sales Growth (%)(%) | 1.0% | -2.8% | -4.3% | -9.1% | 10.2% | 9.8% | 10.6% | 13.0% | 8.0% | 14.7% | 6.4% | 18.9% | |
Adult Nutrition Division (Ensure, Glucerna, Juven, ProSure) International — Reported Sales Growth (%)(%) | 1.3% | -2.0% | -0.9% | -8.9% | 10.9% | 9.2% | 6.1% | 9.5% | 1.5% | 6.4% | 0.8% | 17.4% | |
Nutritional Products Segment Total — Worldwide Revenue ($M)($M)7 | 2,262 | 2,144 | 2,017 | 1,940 | 2,153 | 2,212 | 2,146 | 2,129 | 2,066 | 2,150 | 2,068 | 2,038 | |
Nutritional Products Segment Total — Organic / Comparable Sales Growth (%)(%) | 4.9% | -3.6% | -7.7% | -9.1% | 4.0% | 3.4% | 6.8% | 7.1% | 3.4% | 7.5% | 7.7% | 13.9% | |
Nutritional Products Segment Total — Reported Sales Growth (%)(%) | 5.1% | -3.1% | -6.0% | -8.9% | 4.2% | 2.9% | 3.8% | 4.5% | -0.3% | 3.5% | 5.1% | 12.2% | |
Nutritional Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%) | 0.2% | 0.2% | -0.5% | -2.4% | -1.7% | -3.1% | -3.6% | -2.6% | -0.7% | ||||
Nutritional Products Segment Total — U.S. Revenue ($M)($M)2 | 958 | 871 | 844 | 806 | 888 | 957 | 955 | 928 | 950 | 933 | 878 | 860 | |
Nutritional Products Segment Total U.S. — Organic / Comparable Sales Growth (%)(%) | 7.9% | -9.0% | -11.6% | -13.2% | -6.5% | 2.6% | 10.4% | 10.0% | 11.9% | 6.9% | 8.1% | 8.2% | |
Nutritional Products Segment Total U.S. — Reported Sales Growth (%)(%) | 7.9% | -9.0% | -11.6% | -13.2% | -6.5% | 2.6% | 8.8% | 8.0% | 10.4% | 6.0% | 8.1% | 8.2% | |
Nutritional Products Segment Total — International Revenue ($M)($M)2 | 1,304 | 1,273 | 1,173 | 1,134 | 1,265 | 1,255 | 1,191 | 1,201 | 1,116 | 1,217 | 1,190 | 1,178 | |
Nutritional Products Segment Total International — Organic / Comparable Sales Growth (%)(%) | 2.8% | 0.6% | -4.7% | -5.9% | 13.0% | 4.0% | 4.2% | 4.9% | -2.6% | 7.9% | 7.4% | 18.5% | |
Nutritional Products Segment Total International — Reported Sales Growth (%)(%) | 3.1% | 1.4% | -1.5% | -5.6% | 13.3% | 3.1% | 0.1% | 2.0% | -7.9% | 1.7% | 3.0% | 15.3% | |
Nutritional Products — Segment Research & Development Expense ($M)($M) | 54 | 54 | 52 | 55 | 54 | 52 | 51 | 53 | 53 | 52 | |||
Nutritional Products — Segment Property & Equipment Additions ($M)($M) | 46 | 40 | 71 | 71 | 81 | 79 | 100 | 106 | 103 | 73 | |||
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Worldwide Revenue ($M)($M)4 | 1,195 | 1,164 | 1,089 | 1,046 | 1,097 | 1,059 | 965 | 948 | 994 | 988 | 928 | 918 | |
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Organic / Comparable Sales Growth (%)(%) | 10.9% | 10.7% | 9.4% | 8.7% | 11.1% | 8.7% | 9.3% | 8.8% | 5.4% | 8.8% | 15.4% | 11.4% | |
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Reported Sales Growth (%)(%) | 9.0% | 9.8% | 12.9% | 10.3% | 10.3% | 7.3% | 4.0% | 3.3% | 0.7% | -0.2% | 1.7% | 0.5% | |
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — Foreign Exchange Impact on Sales Growth (%)(%) | 1.6% | -0.8% | -1.4% | -5.3% | -5.5% | -4.7% | -9.0% | -13.7% | -10.9% | ||||
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) — International Revenue ($M)($M)2 | 1,195 | 1,164 | 1,089 | 1,046 | 1,097 | 1,059 | 965 | 948 | 994 | 988 | 928 | 918 | |
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Organic / Comparable Sales Growth (%)(%) | 10.9% | 10.7% | 9.4% | 8.7% | 11.1% | 8.7% | 9.3% | 8.8% | 5.4% | 8.8% | 15.4% | 11.4% | |
Key Emerging Markets (India, China, Brazil, Russia, Colombia, Mexico, Vietnam) International — Reported Sales Growth (%)(%) | 9.0% | 9.8% | 12.9% | 10.3% | 10.3% | 7.3% | 4.0% | 3.3% | 0.7% | -0.2% | 1.7% | 0.5% | |
Other Emerging & International Markets — Worldwide Revenue ($M)($M)4 | 419 | 335 | 337 | 336 | 414 | 324 | 295 | 320 | 412 | 306 | 298 | 304 | |
Other Emerging & International Markets — Organic / Comparable Sales Growth (%)(%) | 1.6% | 2.1% | 7.9% | 1.9% | -2.5% | 4.5% | 3.1% | 7.8% | 11.2% | 5.7% | 8.2% | 0.8% | |
Other Emerging & International Markets — Reported Sales Growth (%)(%) | 1.1% | 3.7% | 14.1% | 5.0% | 0.6% | 5.9% | -1.2% | 5.2% | 8.1% | 3.1% | 7.6% | 0.4% | |
Other Emerging & International Markets — Foreign Exchange Impact on Sales Growth (%)(%) | 3.1% | 3.1% | 1.4% | -4.3% | -2.6% | -3.1% | -2.6% | -0.6% | -0.4% | ||||
Other Emerging & International Markets — International Revenue ($M)($M)2 | 419 | 335 | 337 | 336 | 414 | 324 | 295 | 320 | 412 | 306 | 298 | 304 | |
Other Emerging & International Markets International — Organic / Comparable Sales Growth (%)(%) | 1.6% | 2.1% | 7.9% | 1.9% | -2.5% | 4.5% | 3.1% | 7.8% | 11.2% | 5.7% | 8.2% | 0.8% | |
Other Emerging & International Markets International — Reported Sales Growth (%)(%) | 1.1% | 3.7% | 14.1% | 5.0% | 0.6% | 5.9% | -1.2% | 5.2% | 8.1% | 3.1% | 7.6% | 0.4% | |
Established Pharmaceutical Products Segment Total — Worldwide Revenue ($M)($M)6 | 1,614 | 1,499 | 1,426 | 1,382 | 1,511 | 1,383 | 1,260 | 1,268 | 1,406 | 1,294 | 1,226 | 1,222 | |
Established Pharmaceutical Products Segment Total — Organic / Comparable Sales Growth (%)(%) | 8.4% | 8.7% | 9.0% | 7.0% | 7.1% | 7.7% | 7.8% | 8.5% | 7.0% | 8.1% | 13.7% | 8.8% | |
Established Pharmaceutical Products Segment Total — Reported Sales Growth (%)(%) | 6.8% | 8.4% | 13.2% | 9.0% | 7.5% | 6.9% | 2.7% | 3.8% | 2.7% | 0.6% | 3.1% | 0.5% | |
Established Pharmaceutical Products Segment Total — Foreign Exchange Impact on Sales Growth (%)(%) | 2.0% | 0.4% | -0.8% | -5.1% | -4.7% | -4.3% | -7.5% | -10.6% | -8.3% | ||||
Established Pharmaceutical Products Segment Total — International Revenue ($M)($M)2 | 1,614 | 1,499 | 1,426 | 1,382 | 1,511 | 1,383 | 1,260 | 1,268 | 1,406 | 1,294 | 1,226 | 1,222 | |
Established Pharmaceutical Products Segment Total International — Organic / Comparable Sales Growth (%)(%) | 8.4% | 8.7% | 9.0% | 7.0% | 7.1% | 7.7% | 7.8% | 8.5% | 7.0% | 8.1% | 13.7% | 8.8% | |
Established Pharmaceutical Products Segment Total International — Reported Sales Growth (%)(%) | 6.8% | 8.4% | 13.2% | 9.0% | 7.5% | 6.9% | 2.7% | 3.8% | 2.7% | 0.6% | 3.1% | 0.5% | |
Established Pharmaceuticals — Segment Research & Development Expense ($M)($M) | 48 | 41 | 49 | 42 | 43 | 42 | 45 | 46 | 44 | 41 | |||
Established Pharmaceuticals — Segment Property & Equipment Additions ($M)($M) | 36 | 20 | 59 | 38 | 39 | 33 | 65 | 52 | 37 | 29 | |||
Total Company Consolidated Net Sales — Worldwide Revenue ($M)($M)6 | 13,013 | 12,593 | 11,164 | 11,459 | 11,369 | 11,142 | 10,358 | 10,974 | 10,635 | 10,377 | 9,964 | 10,241 | |
Total Company Consolidated Net Sales — Organic / Comparable Sales Growth (%)(%) | 7.0% | 4.8% | 3.7% | 3.0% | 5.5% | 6.9% | 6.9% | 8.8% | 7.6% | 7.4% | 4.7% | 2.1% | |
Total Company Consolidated Net Sales — Reported Sales Growth (%)(%) | 14.5% | 13.0% | 7.8% | 4.4% | 6.9% | 7.4% | 4.0% | 7.2% | 4.9% | 4.0% | 2.2% | 1.5% | |
Total Company Consolidated Net Sales — Foreign Exchange Impact on Sales Growth (%)(%) | 1.4% | 1.4% | 0.5% | -2.8% | -1.4% | -2.5% | -3.5% | -2.9% | -0.8% | ||||
Total Company Consolidated Net Sales — U.S. Revenue ($M)($M)2 | 5,504 | 5,216 | 4,274 | 4,383 | 4,299 | 4,276 | 4,168 | 4,341 | 4,202 | 3,934 | 3,846 | 3,949 | |
Total Company Consolidated Net Sales U.S. — Organic / Comparable Sales Growth (%)(%) | 7.9% | 3.5% | 2.5% | 0.9% | 2.3% | 8.7% | 8.8% | 13.5% | 11.0% | 9.0% | 10.0% | 7.1% | |
Total Company Consolidated Net Sales U.S. — Reported Sales Growth (%)(%) | 28.0% | 22.0% | 2.5% | 0.9% | 2.3% | 8.7% | 8.4% | 10.0% | 10.1% | 4.7% | -2.1% | -6.4% | |
Total Company Consolidated Net Sales — International Revenue ($M)($M)2 | 7,509 | 7,377 | 6,890 | 7,076 | 7,070 | 6,866 | 6,190 | 6,633 | 6,433 | 6,443 | 6,118 | 6,292 | |
Total Company Consolidated Net Sales International — Organic / Comparable Sales Growth (%)(%) | 6.4% | 5.8% | 4.6% | 4.3% | 7.6% | 5.8% | 5.7% | 8.1% | 6.5% | 9.4% | 11.3% | 13.4% | |
Total Company Consolidated Net Sales International — Reported Sales Growth (%)(%) | 6.2% | 7.5% | 11.3% | 6.7% | 9.9% | 6.6% | 1.2% | 5.4% | 1.7% | 3.6% | 5.2% | 7.2% | |
Total Company — Organic Sales Growth Excl. COVID-19 Testing (%)(%) | 3.8% | 7.5% | 7.5% | 10.1% | 8.2% | 9.3% | 10.8% | 11.0% | |||||
Non-GAAP Adjusted Diluted Earnings Per Share ($/share)($)2 | 1.42 | 1.31 | 1.15 | 1.50 | 1.30 | 1.26 | 1.09 | 1.34 | 1.21 | 1.14 | 0.98 | 1.19 | |
GAAP Diluted Earnings Per Share — Reconciliation Table ($/share)($) | 0.53 | 0.53 | 0.61 | 1.01 | 0.94 | 1.01 | 0.76 | 5.27 | 0.94 | 0.74 | 0.70 | 0.91 | |
Specified Items Impact on Diluted EPS ($/share)($) | 0.89 | 0.78 | 0.54 | 0.49 | 0.36 | 0.25 | 0.33 | 0.27 | 0.40 | 0.28 | 0.28 | ||
Non-GAAP Adjusted Net Earnings ($M)($M)7 | 2,477 | 2,290 | 2,022 | 2,630 | 2,278 | 2,213 | 1,919 | 2,349 | 2,119 | 2,003 | 1,729 | 2,094 | |
GAAP Net Earnings — Reconciliation Table ($M)($M) | 920 | 928 | 1,077 | 1,776 | 1,644 | 1,779 | 1,325 | 9,229 | 1,646 | 1,302 | 1,225 | 1,594 | |
Specified Items After-Tax Net Impact ($M)($M) | 1,557 | 1,362 | 945 | 854 | 634 | 434 | 594 | -6,880 | 473 | 701 | 504 | 500 | |
Non-GAAP Adjusted Earnings Before Taxes ($M)($M) | 2,920 | 2,701 | 2,385 | 3,086 | 2,728 | 2,650 | 2,298 | 2,763 | 2,492 | 2,356 | 2,035 | 2,435 | |
Non-GAAP Adjusted Gross Margin ($M)($M) | 7,448 | 7,307 | 6,284 | 6,543 | 6,344 | 6,346 | 5,918 | 6,240 | 5,983 | 5,809 | 5,547 | 5,722 | |
Non-GAAP Adjusted Research & Development Expense ($M)($M) | 892 | 867 | 743 | 706 | 730 | 705 | 689 | 690 | 694 | 657 | 663 | 622 | |
Non-GAAP Adjusted Selling, General & Administrative Expense ($M)($M) | 3,505 | 3,597 | 3,267 | 2,875 | 3,004 | 3,090 | 3,051 | 2,886 | 2,890 | 2,879 | 2,925 | 2,689 | |
Intangible Assets Amortization Expense ($M)($M)5 | 841 | 658 | 422 | 422 | 420 | 420 | 420 | 465 | 470 | 471 | 472 | 481 | |
Forecasted Annual Intangible Amortization — Year 1 ($M)($M) | 2,300 | 2,300 | 1,500 | 1,500 | 1,500 | 1,500 | 1,700 | 1,700 | 1,700 | 1,700 | 1,900 | ||
Forecasted Annual Intangible Amortization — Year 2 ($M)($M) | 1,800 | 1,800 | 1,200 | 1,200 | 1,200 | 1,200 | 1,500 | 1,600 | 1,600 | 1,600 | 1,700 | ||
Forecasted Annual Intangible Amortization — Year 3 ($M)($M) | 1,700 | 1,700 | 650 | 700 | 700 | 700 | 1,200 | 1,300 | 1,300 | 1,300 | 1,600 | ||
Forecasted Annual Intangible Amortization — Year 4 ($M)($M) | 1,500 | 1,500 | 608 | 600 | 600 | 600 | 668 | 700 | 700 | 700 | 1,300 | ||
Forecasted Annual Intangible Amortization — Year 5 ($M)($M) | 363 | 605 | 700 | ||||||||||
Effective Tax Rate — Non-GAAP Adjusted (%)(%)1 | 15.2% | 15.2% | 15.2% | 14.8% | 16.5% | 16.5% | 16.5% | 15.0% | 15.0% | 15.0% | 15.0% | 14.0% | |
Effective Tax Rate — GAAP Reported (%)(%) | 25.3% | 39.1% | 25.6% | 24.7% | 24.6% | 17.3% | 25.5% | -354.6% | 15.2% | 19.0% | 14.7% | 11.2% | |
Quarterly Common Dividend Declared ($/share)($) | 0.63 | 0.63 | 0.63 | 0.63 | 0.59 | 0.59 | 0.59 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | |
Total Inventories Net ($M)($M)3 | 7,315 | 6,989 | 6,488 | 6,708 | 6,954 | 6,639 | 6,194 | 6,813 | 6,814 | 6,827 | 6,570 | ||
Finished Goods Inventory ($M)($M) | 4,512 | 4,274 | 3,976 | 4,130 | 4,319 | 4,063 | 3,700 | 4,173 | 4,060 | 4,063 | 3,946 | ||
Work in Process Inventory ($M)($M) | 1,023 | 994 | 904 | 961 | 962 | 890 | 840 | 877 | 880 | 881 | 807 | ||
Raw Materials Inventory ($M)($M) | 1,780 | 1,721 | 1,608 | 1,617 | 1,673 | 1,686 | 1,654 | 1,763 | 1,874 | 1,883 | 1,817 | ||
Property, Plant & Equipment — Gross Carrying Value ($M)($M)5 | 26,469 | 25,737 | 25,222 | 24,816 | 24,472 | 23,418 | 22,740 | 22,857 | 22,061 | 22,055 | 21,933 | ||
Machinery & Equipment — Gross ($M)($M) | 17,571 | 15,517 | 15,179 | ||||||||||
Buildings — Gross ($M)($M) | 4,543 | 4,207 | 4,161 | ||||||||||
Construction in Progress ($M)($M) | 2,567 | 2,488 | 2,064 | ||||||||||
Land ($M)($M) | 541 | 528 | 529 | ||||||||||
Accumulated Depreciation ($M)($M) | 13,657 | 13,360 | 13,406 | 13,312 | 13,077 | 12,486 | 12,082 | 12,236 | 11,828 | 11,948 | 11,779 | ||
Common Shares Repurchased — Value ($M)($M)1 | 1,040 | 18 | 301 | 303 | 1 | 24 | 369 | 752 | 0 | 22 | 304 | ||
Common Shares Repurchased — Volume (Million Shares)(M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Defined Benefit Pension Plans — Projected Benefit Obligation ($M)($M)2 | 9,880 | 9,450 | 10,030 | ||||||||||
Defined Benefit Pension Plans — Fair Value of Plan Assets ($M)($M) | 16,247 | 14,143 | 13,085 | ||||||||||
Post-Retirement Medical & Dental Plans — Benefit Obligation ($M)($M) | 1,386 | 1,166 | 1,181 | ||||||||||
Abbott India Limited — Revenue from Operations (INR Crores)9 | 1,814 | 1,710 | 1,724 | 1,757 | 1,738 | 1,605 | 1,614 | 1,633 | 1,558 | 1,439 | 1,437 | ||
Abbott India — Operating Profit / EBITDA (INR Crores) | 522 | 481 | 463 | 502 | 446 | 429 | 436 | 439 | 391 | 330 | 388 | ||
Abbott India — Operating Profit Margin (%)(%) | 29.0% | 28.0% | 27.0% | 29.0% | 26.0% | 27.0% | 27.0% | 27.0% | 25.0% | 23.0% | 27.0% | ||
Abbott India — Operating Expenses (INR Crores) | 1,291 | 1,229 | 1,261 | 1,255 | 1,293 | 1,176 | 1,178 | 1,194 | 1,167 | 1,109 | 1,049 | ||
Abbott India — Other / Treasury Income (INR Crores) | 75 | 76 | 70 | 70 | 73 | 76 | 72 | 60 | 67 | 81 | 56 | ||
Abbott India — Depreciation & Amortization (INR Crores) | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 18 | 18 | 18 | ||
Abbott India — Profit Before Tax (INR Crores) | 572 | 531 | 509 | 546 | 493 | 483 | 488 | 479 | 437 | 390 | 422 | ||
Abbott India — Effective Tax Rate (%)(%) | 25.0% | 26.0% | 26.0% | 24.0% | 26.0% | 24.0% | 26.0% | 25.0% | 25.0% | 26.0% | 26.0% | ||
Abbott India — Net Profit (INR Crores) | 429 | 395 | 376 | 415 | 366 | 367 | 361 | 359 | 328 | 287 | 311 | ||
Abbott India — Earnings Per Share (INR / Share) | 202 | 186 | 177 | 195 | 172 | 173 | 170 | 169 | 154 | 135 | 146 | ||
Abbott India Limited — Number of Registered Shareholders4 | 75,769 | 78,320 | 75,866 | 75,801 | 71,199 | 67,584 | 69,934 | 67,892 | 69,449 | 71,588 | 69,382 | 72,252 | |
Abbott India — Promoter (Abbott Parent) Shareholding (%)(%) | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | |
Abbott India — Domestic Institutional Investors (DIIs) Shareholding (%)(%) | 9.0% | 8.8% | 8.9% | 9.0% | 9.1% | 9.2% | 8.9% | 9.0% | 9.0% | 8.8% | 8.9% | 8.7% | |
Abbott India — Foreign Institutional Investors (FIIs) Shareholding (%)(%) | 0.4% | 0.4% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | |
Abbott India — Public / Retail Shareholding (%)(%) | 15.6% | 15.9% | 15.8% | 15.8% | 15.7% | 15.7% | 15.9% | 15.9% | 15.9% | 16.0% | 15.9% | 16.1% | |
U.S. FDA 510(k) Device Clearances — Abbott5 | 6 | 8 | 2 | 5 | 9 | 8 | 7 | 5 | 4 | 5 | 2 | 5 | |
U.S. FDA 510(k) Device Clearances — Total U.S. MedTech Industry | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
U.S. FDA Premarket Approvals (PMA Original & Supplements) — Abbott | 65 | 75 | 70 | 50 | 69 | 87 | 53 | 97 | 71 | 66 | 54 | 92 | |
U.S. FDA Premarket Approvals (PMA) — Total U.S. MedTech Industry | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
U.S. FDA Medical Device Recall Events — Abbott | 0 | 4 | 5 | 9 | 4 | 17 | 0 | 14 | 20 | 5 | 7 | 4 | |
U.S. FDA Enforcement Recall Actions — Abbott | 0 | 4 | 5 | 9 | 4 | 17 | 5 | 9 | 20 | 5 | 8 | 3 | |
U.S. FDA MAUDE Adverse Event MDR Reports — Abbott Total4 | 295,931 | 143,866 | 29,400 | 23,684 | 25,298 | 23,390 | 20,979 | 22,373 | 25,010 | 22,310 | 20,460 | 22,102 | |
FDA MAUDE MDR Reports — Device Malfunction (Abbott) | 285,131 | 132,390 | 22,058 | 16,580 | 16,531 | 14,832 | 12,638 | 11,987 | 14,455 | 12,090 | 10,656 | 11,988 | |
FDA MAUDE MDR Reports — Patient Injury (Abbott) | 10,413 | 11,120 | 7,075 | 6,857 | 8,538 | 8,410 | 8,212 | 10,220 | 10,428 | 10,069 | 9,657 | 9,942 | |
FDA MAUDE MDR Reports — Death (Abbott) | 265 | 354 | 259 | 244 | 227 | 145 | 126 | 162 | 124 | 148 | 141 | 161 | |
FDA MAUDE Adverse Event MDR Reports — Total MedTech Industry | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
NIH ClinicalTrials.gov — Cumulative Abbott-Sponsored Clinical Studies1 | |||||||||||||
ClinicalTrials.gov — New Abbott Clinical Studies Started | 12 | 4 | 9 | 11 | 10 | 17 | 7 | 14 | 13 | 8 | 14 | 10 | |
U.S. PPI — Surgical & Medical Instruments Manufacturing (Index)(×)5 | 163.40 | 162.90 | 161.70 | 159.60 | 157.80 | 156.90 | 157.10 | 155.20 | 154.40 | 154.10 | 153.60 | 151.00 | |
U.S. PPI — Surgical Appliances & Supplies Manufacturing (Index)(×) | 269.30 | 263.80 | 253.80 | 251.40 | 249.60 | 249.50 | 248.70 | 245.40 | 245.10 | 243.70 | 240.10 | 238.50 | |
U.S. PPI — Electromedical & Electrotherapeutic Apparatus (Index)(×) | 92.80 | 92.10 | 92.00 | 91.60 | 90.70 | 90.30 | 90.10 | 89.50 | 89.30 | 88.40 | 88.30 | 87.80 | |
U.S. CPI — Medical Care Commodities (Index)(×) | 404.90 | 410.40 | 416.80 | 417.00 | 416.50 | 416.00 | 412.60 | 415.90 | 414.50 | 408.30 | 410.10 | ||
U.S. CPI — Medical Care Services (Index)(×) | 654.70 | 650.90 | 647.60 | 638.40 | 630.60 | 623.40 | 619.60 | 613.00 | 611.40 | 605.80 | 597.90 | ||
U.S. Census QSS — General Medical & Surgical Hospitals Revenue ($M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Reportable Segments Total Operating Earnings ($M)($M) | 1,693 | 1,345 | 2,251 | 2,057 | 2,052 | 1,693 | 1,911 | 1,859 | 1,669 | 1,386 | 1,780 | ||
Medical Devices — Segment Cost of Products Sold ($M)($M)3 | 1,925 | 1,814 | -12,096 | 1,767 | 1,758 | 1,598 | -11,187 | 1,605 | 1,627 | 1,547 | |||
Diagnostic Products — Segment Cost of Products Sold ($M)($M) | 1,532 | 1,242 | -8,650 | 1,290 | 1,224 | 1,152 | -8,666 | 1,280 | 1,203 | 1,188 | |||
Nutritional Products — Segment Cost of Products Sold ($M)($M) | 1,148 | 1,089 | -8,071 | 1,223 | 1,155 | 1,124 | -7,919 | 1,151 | 1,148 | 1,088 | |||
Established Pharmaceutical Products — Segment Cost of Products Sold ($M)($M) | 650 | 644 | -4,529 | 714 | 631 | 569 | -4,263 | 644 | 591 | 584 | |||
Medical Devices — Segment Total Assets ($M)($M)4 | 11,406 | 10,983 | 10,689 | 10,576 | 10,555 | 10,034 | 9,472 | 9,029 | |||||
Medical Devices — Segment Depreciation & Amortization ($M)($M) | 106 | 100 | 99 | 97 | 94 | 88 | 82 | 87 | 87 | 87 | |||
Diagnostic Products — Segment Depreciation & Amortization ($M)($M) | 165 | 144 | 136 | 136 | 135 | 126 | 134 | 129 | 129 | 129 | |||
Nutritional Products — Segment Depreciation & Amortization ($M)($M) | 51 | 50 | 42 | 47 | 44 | 42 | 43 | 38 | 39 | 39 | |||
Established Pharmaceutical Products — Segment Depreciation & Amortization ($M)($M) | 25 | 30 | 25 | 28 | 25 | 23 | 25 | 23 | 24 | 24 | |||
Geographic Revenue — United States ($M)($M)1 | 5,216 | 4,274 | 4,383 | 4,299 | 4,276 | 4,168 | 4,341 | 4,202 | 3,934 | 3,846 | 3,949 | ||
Long-Lived Assets — United States ($M)($M) | 11,900 | 10,300 | 8,900 | ||||||||||
Consolidated Net Sales ($M)($M)11 | 12,593 | 11,164 | 11,459 | 11,369 | 11,142 | 10,358 | 10,974 | 10,635 | 10,377 | 9,964 | 10,241 | ||
Cost of Products Sold ($M)($M) | 5,325 | 4,890 | 4,922 | 5,075 | 4,854 | 4,468 | 4,942 | 4,698 | 4,603 | 4,463 | 4,556 | ||
GAAP Gross Margin ($M)($M) | 6,544 | 6,610 | 5,852 | 6,115 | 5,874 | 5,868 | 5,470 | 5,567 | 5,467 | 5,303 | 5,029 | 5,204 | |
Research & Development Expense ($M)($M) | 892 | 767 | 735 | 766 | 725 | 716 | 749 | 713 | 698 | 684 | 700 | ||
Selling, General & Administrative Expense ($M)($M) | 4,025 | 3,740 | 3,129 | 3,051 | 3,091 | 3,061 | 2,907 | 2,895 | 2,936 | 2,959 | 2,724 | ||
Operating Earnings ($M)($M) | 1,693 | 1,345 | 2,251 | 2,057 | 2,052 | 1,693 | 1,911 | 1,859 | 1,669 | 1,386 | 1,780 | ||
Interest Expense ($M)($M) | 351 | 174 | 120 | 121 | 121 | 131 | 136 | 142 | 140 | 141 | 159 | ||
Earnings Before Taxes ($M)($M) | 1,524 | 1,449 | 2,358 | 2,180 | 2,150 | 1,778 | 2,030 | 1,940 | 1,607 | 1,436 | 1,795 | ||
Taxes on Earnings ($M)($M) | 596 | 372 | 582 | 536 | 371 | 453 | -7,199 | 294 | 305 | 211 | 201 | ||
Net Earnings ($M)($M) | 928 | 1,077 | 1,776 | 1,644 | 1,779 | 1,325 | 9,229 | 1,646 | 1,302 | 1,225 | 1,594 | ||
Diluted Earnings Per Common Share ($/share)($) | 0.53 | 0.61 | 0.94 | 1.01 | 0.76 | 0.94 | 0.74 | 0.70 | |||||
Weighted-Average Diluted Shares Outstanding (Millions)(M) | 1,743 | 1,747 | 1,749 | 1,751 | 1,747 | 1,748 | 1,751 | 1,750 | |||||
Total Assets ($M)($M)11 | 109,215 | 110,429 | 86,713 | 84,181 | 83,999 | 81,448 | 81,414 | 74,356 | 73,017 | 72,467 | 73,214 | ||
Cash & Cash Equivalents ($M)($M) | 5,104 | 6,803 | 8,522 | 7,511 | 6,951 | 6,532 | 7,616 | 7,558 | 6,987 | 6,284 | 6,896 | ||
Short-Term Investments ($M)($M) | 499 | 492 | 417 | 222 | 331 | 312 | 351 | 230 | 232 | 367 | 383 | ||
Trade Accounts Receivable, Net ($M)($M) | 8,599 | 8,210 | 7,929 | 8,138 | 7,972 | 7,327 | 6,925 | 7,051 | 6,854 | 6,605 | 6,565 | ||
Total Inventories ($M)($M) | 7,315 | 6,989 | 6,488 | 6,708 | 6,954 | 6,639 | 6,194 | 6,813 | 6,814 | 6,827 | 6,570 | ||
Total Current Assets ($M)($M) | 24,517 | 25,508 | 25,996 | 24,839 | 24,468 | 23,153 | 23,656 | 23,802 | 23,119 | 22,376 | 22,670 | ||
Net Property & Equipment ($M)($M) | 12,812 | 12,377 | 11,816 | 11,504 | 11,395 | 10,932 | 10,658 | 10,621 | 10,233 | 10,107 | 10,154 | ||
Goodwill ($M)($M) | 35,244 | 35,221 | 24,035 | 23,971 | 23,952 | 23,359 | 23,108 | 23,658 | 23,308 | 23,383 | 23,679 | ||
Intangible Assets, Net of Amortization ($M)($M) | 17,211 | 17,875 | 5,526 | 5,598 | 5,920 | 6,261 | 6,647 | 7,352 | 7,827 | 8,296 | 8,815 | ||
Total Current Liabilities ($M)($M) | 17,814 | 18,377 | 16,496 | 14,582 | 13,439 | 13,004 | 14,157 | 14,902 | 13,760 | 14,021 | 13,841 | ||
Long-Term Debt ($M)($M) | 29,603 | 29,638 | 9,896 | 11,596 | 12,930 | 12,736 | 12,625 | 12,825 | 13,139 | 12,576 | 13,599 | ||
Total Shareholders' Investment / Equity ($M)($M) | 51,110 | 52,061 | 52,130 | 50,954 | 50,565 | 48,811 | 47,664 | 39,796 | 39,318 | 38,810 | 38,603 | ||
Operating Cash Flow ($M)($M)3 | 2,488 | 1,315 | 3,315 | 2,787 | 2,047 | 1,417 | 2,868 | 2,705 | 1,960 | 1,025 | 3,038 | ||
Capital Expenditures ($M)($M) | 497 | 399 | 689 | 496 | 502 | 484 | 720 | 556 | 533 | 398 | 755 | ||
Dividends Paid ($M)($M) | 1,102 | 1,098 | 1,030 | 1,031 | 1,029 | 1,026 | 958 | 960 | 961 | 957 | 888 | ||
Stock-Based Compensation Expense ($M)($M) | 168 | 317 | 113 | 120 | 142 | 289 | 111 | 117 | 141 | 304 | 114 | ||
20 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational KPI Drivers (Groups 1–4): Flagship Continuous Glucose Monitoring (FreeStyle Libre & Lingo) sales and organic growth, all 7 Medical Devices divisions (Diabetes Care, Electrophysiology, Structural Heart, Rhythm Management, Heart Failure, Vascular, Neuromodulation), all 5 Diagnostics divisions (Core Laboratory, Cancer Diagnostics / Exact Sciences acquired March 2026, Rapid & Molecular Diagnostics, and legacy Rapid/Molecular/Point of Care) + COVID-19 testing sales & ex-COVID base growth, Nutritional Products (Pediatric & Adult + WIC state contracts & NEC reserves), and Established Pharmaceuticals (Key Emerging Markets vs. Other Markets).
- Standalone / Parent-Only Assessment (Step 3 & Step 4): Abbott Laboratories files consolidated financial statements under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary operations are captured directly from self-reported filings in Group 7: 74.99%-owned listed Indian subsidiary Abbott India Limited (NSE: ABBOTINDIA, in INR Crores) and 4 UK operating subsidiaries (UK Gender Pay Gap filings).
- Period Splitting (Step 4): Missing standalone quarters for CGM revenue (where 10-Q/10-K reported 6M, 9M, and FY cumulative totals) and cash flow statement quarters (Q2–Q4) are derived strictly via 6M − Q1, 9M − 6M, and FY − 9M.
Không hiện vì thiếu các kỳ gần đây (4)
- FreeStyle Libre Global Patient Count (~6M–7M users) — Disclosed only as approximate bounds ('more than 6 million', 'nearly 7 million') in earnings calls/releases; excluded per Step 5 bound rule.
- Annual People Reached Globally (>2 billion people / 3 billion lives目标) — Disclosed as bound ('more than 2 billion') in Annual Report / ESG; excluded per Step 5 bound rule.
- Scope 3 GHG Emissions by Category (ktCO2e) — Only 1–2 years of complete category disaggregation in ESG 2024; excluded due to insufficient multi-period continuity.
- Diagnostics Legacy Subsegments (Rapid Diagnostics, Molecular Diagnostics, Point of Care) post-FY2025Q4 — Combined into 'Rapid and Molecular Diagnostics' starting Q1 2026; legacy series retained through FY2025Q4 and new combined series tracked from Q1 2026.
Dữ liệu cập nhật 2026-10-29.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Continuous Glucose Monitoring (FreeStyle Libre) & Medical Devices 7 Divisions (Key Chính)
- Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M)29 kỳ
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M)44 kỳ
- Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Worldwide Revenue ($M) ($M)43 kỳ
- Structural Heart Division (MitraClip, TriClip, Navitor TAVI, Amulet LAA, Tendyne) — Worldwide Revenue ($M) ($M)43 kỳ
- Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) — Worldwide Revenue ($M) ($M)43 kỳ
- Heart Failure Division (HeartMate 3 LVAD & CardioMEMS HF Sensor) — Worldwide Revenue ($M) ($M)43 kỳ
- Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — Worldwide Revenue ($M) ($M)44 kỳ
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M) ($M)43 kỳ
- Medical Devices Segment Total — Worldwide Revenue ($M) ($M)44 kỳ
Diagnostics — Core Lab, Cancer Diagnostics (Exact Sciences), Rapid/Molecular & COVID-19 Testing
- Core Laboratory Diagnostics (Alinity ci/i/c/m/h/s, ARCHITECT, GLP Track) — Worldwide Revenue ($M) ($M)44 kỳ
- Cancer Diagnostics Division (Exact Sciences — Cologuard, Oncotype DX & SimpleScreen CRC) — Worldwide Revenue ($M) ($M)5 kỳ
- Rapid and Molecular Diagnostics Division (Combined Subsegment from Q1 2026) — Worldwide Revenue ($M) ($M)5 kỳ
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M) ($M)33 kỳ
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M) ($M)41 kỳ
- Point of Care Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — i-STAT & i-STAT Alinity) — Worldwide Revenue ($M) ($M)41 kỳ
- Global COVID-19 Testing-Related Sales ($M) ($M)19 kỳ
- Diagnostics Segment Total — Worldwide Revenue ($M) ($M)44 kỳ
Nutritional Products — Pediatric & Adult Divisions, WIC State Contracts & Volume/Price
Established Pharmaceuticals (Branded Generics) — Key Emerging Markets vs. Other Markets
Consolidated Volume/Price/FX Decomposition, Gross-to-Net Sales Rebates, Non-GAAP & Footnotes
- Total Company Consolidated Net Sales — Worldwide Revenue ($M) ($M)44 kỳ
- Rebates & Chargebacks Charged Against Gross Sales ($M) ($M)15 kỳ
- Non-GAAP Adjusted Diluted Earnings Per Share ($/share) ($)23 kỳ
- Non-GAAP Adjusted Net Earnings ($M) ($M)23 kỳ
- Effective Tax Rate — Non-GAAP Adjusted (%) (%)47 kỳ
- Quarterly Common Dividend Declared ($/share) ($)31 kỳ
- Total Inventories Net ($M) ($M)54 kỳ
- Property, Plant & Equipment — Gross Carrying Value ($M) ($M)54 kỳ
- Common Shares Repurchased — Value ($M) ($M)33 kỳ
- Defined Benefit Pension Plans — Projected Benefit Obligation ($M) ($M)11 kỳ
Global Workforce, Compensation (DEF 14A), 3TG Conflict Minerals (Form SD) & ESG Operations
- Global Workforce Headcount (Employees)10 kỳ
- Median Employee Total Annual Compensation ($) ($)7 kỳ
- Independent Auditor (Ernst & Young LLP) Total Fees ($M) ($M)8 kỳ
- Confirmed Known 3TG Processing Facilities / Smelters in Supply Chain11 kỳ
- Abbott Global Net Price Change vs. Inflation (%) (%)5 kỳ
- Philanthropic Social Investing — Cash & Product Donations ($M) ($M)9 kỳ
- Total Spend with Small & Diverse Suppliers ($M) ($M)5 kỳ
- Total Recordable Incident Rate (TRIR — per 200,000 Hours Worked) (×)9 kỳ
- Total Scope 1 + Scope 2 Greenhouse Gas Emissions — Market-Based (ktCO2e)9 kỳ
- Total Energy Consumption (1,000 Gigajoules)9 kỳ
- Total Water Withdrawal (Million Liters)7 kỳ
- Total Operational Waste Generated (Metric Tons)7 kỳ
Subsidiaries Self-Reported Data — Abbott India Limited (NSE: ABBOTINDIA) & UK Operating Subsidiaries
- Abbott India Limited — Revenue from Operations (INR Crores)13 kỳ
- Abbott India Limited — Total Assets (INR Crores)11 kỳ
- Abbott India Limited — Number of Registered Shareholders12 kỳ
- Abbott Laboratories Ltd (UK Co. 00329102) — Mean Hourly Gender Pay Gap (%) (%)8 kỳ
- Abbott Diabetes Care Ltd (UK Co. 02548046 — Witney FreeStyle Libre Sensor Hub) — Mean Hourly Pay Gap (%) (%)8 kỳ
- Abbott Medical U.K. Ltd (UK Co. 02423907 — Cardiovascular Devices) — Mean Hourly Pay Gap (%) (%)3 kỳ
- Abbott Toxicology Ltd (UK Co. 05396234 — Rapid Diagnostics) — Mean Hourly Pay Gap (%) (%)8 kỳ
External MedTech Regulatory (openFDA), ClinicalTrials.gov, Federal Contracts & FRED Benchmarks
- U.S. FDA 510(k) Device Clearances — Abbott153 kỳ
- U.S. FDA MAUDE Adverse Event MDR Reports — Abbott Total153 kỳ
- NIH ClinicalTrials.gov — Cumulative Abbott-Sponsored Clinical Studies12 kỳ
- U.S. Federal Government Contract Obligations to Abbott — Total ($M) ($M)10 kỳ
- U.S. PPI — Surgical & Medical Instruments Manufacturing (Index) (×)141 kỳ
Reportable Segments & Country Geography Breakdown (Database Context)
Consolidated Financial Statements — Income, Balance Sheet & Cash Flows (Database Context)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Abbott Laboratories
- SEC Filing (0001628280-26-002982) ↗
- SEC Filing (0001628280-26-066601) ↗
- Abbott 2024 Global Sustainability Report ↗
- SEC Filing (0001628280-26-050134) ↗
- SEC Filing (0001628280-26-010185) ↗
- U.S. FDA openFDA Device Clearances, Approvals, Recalls & MAUDE MDR ↗
- Form 10-Q (filed 2026-07-28) ↗
- Form 10-K (filed 2026-02-20) ↗
- Abbott India Limited (NSE: ABBOTINDIA) Consolidated Financial & Shareholding Filings (Screener.in) ↗
- Federal Reserve FRED / U.S. BLS & Census Bureau ↗
- SEC Filing (0001308179-26-000064) ↗
- Abbott 2025 Annual Report & Shareholder Letter ↗
See a number that looks wrong?